– In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF <50% – – On track to deliver full 12-week Part D readout in 2Q 2026 and Phase 3 start in 4Q 2026 – BOULDER, Colo., Dec. 24,…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Denver Firm Serves Exclusively Nonprofit and Government Clients DENVER, March 17, 2023 /PRNewswire/ — Lasso Digital CEO Taylor Rosty was recently named one of ColoradoBiz’s Top 25 Young Professionals. The award recognizes top achievers under […]
The Accure Laser System is the next generation light-based platform for the treatment of acne. The Accure Laser is the first 1726nm-based laser platform with both FDA and CE Mark clearances. BOULDER, Colo., Nov. 22, […]
With her favorite Taylor Swift songs playing in the background and her team of healthcare providers cheering her on, Chenille James stood up from her hospital bed. Her destination was just outside the door, her […]
Copyright © 2026 Biotech Networks
